146 related articles for article (PubMed ID: 37681021)
1. Case Report: A rare case of recurrent ascites after anti-Claudin18.2 antibody therapy for metastatic gastric cancer while responding sustainingly.
Liu J; Jiang D; Lei Q; Zhu Q; Zhu H
Front Oncol; 2023; 13():1211668. PubMed ID: 37681021
[TBL] [Abstract][Full Text] [Related]
2. Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: a case report.
Zhong G; Zhang X; Guo Z; Gao Y; Zhao B; Liu X; Chen L; Qiao J; Yu C; Wang L; Li Y; Yu L
Front Immunol; 2024; 15():1325860. PubMed ID: 38487523
[TBL] [Abstract][Full Text] [Related]
3. Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer.
Xu Q; Jia C; Ou Y; Zeng C; Jia Y
Front Oncol; 2024; 14():1371421. PubMed ID: 38511141
[TBL] [Abstract][Full Text] [Related]
4. Progress of Clinical Studies Targeting Claudin18.2 for the Treatment of Gastric Cancer.
Jin WM; Zhu Y; Cai ZQ; He N; Yu ZQ; Li S; Yang JY
Dig Dis Sci; 2024 May; ():. PubMed ID: 38769225
[TBL] [Abstract][Full Text] [Related]
5. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
Kubota Y; Shitara K
Ther Adv Med Oncol; 2024; 16():17588359231217967. PubMed ID: 38188462
[TBL] [Abstract][Full Text] [Related]
6. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy.
Cao W; Xing H; Li Y; Tian W; Song Y; Jiang Z; Yu J
Biomark Res; 2022 May; 10(1):38. PubMed ID: 35642043
[TBL] [Abstract][Full Text] [Related]
7. Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104/cadonilimab (PD-1/CTLA-4 bispecific): A case report.
Peng J; Zhu Q; Peng Z; Chen Z; Liu Y; Liu B
Front Immunol; 2022; 13():1049518. PubMed ID: 36569905
[TBL] [Abstract][Full Text] [Related]
8. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
[No Abstract] [Full Text] [Related]
9. Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance.
Chen KH; Yuan CT; Tseng LH; Shun CT; Yeh KH
J Hematol Oncol; 2016 Mar; 9():29. PubMed ID: 27012666
[TBL] [Abstract][Full Text] [Related]
10. Claudin18.2 in Advanced Gastric Cancer.
Inamoto R; Takahashi N; Yamada Y
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136288
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
[TBL] [Abstract][Full Text] [Related]
12. Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report.
Zhou JH; Yi QJ; Li MY; Xu Y; Dong Q; Wang CY; Liu HY
World J Clin Cases; 2024 Feb; 12(4):820-827. PubMed ID: 38322681
[TBL] [Abstract][Full Text] [Related]
13. Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer.
Xu B; Chen F; Zhang X; Wang Z; Che K; Wu N; Yu L; Fan X; Liu B; Wei J
Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681738
[TBL] [Abstract][Full Text] [Related]
14. Treatment with Ramucirumab-paclitaxel in a metastatic gastric cancer patient undergoing hemodialysis: A case report.
Yang MJ; Choi YJ; Kim HJ; Kim DY; Seol YM
Medicine (Baltimore); 2021 Feb; 100(7):e24795. PubMed ID: 33607838
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study.
Xiang J; Gong W; Sun P; Wang X; Liu A
J Gastrointest Oncol; 2022 Dec; 13(6):2874-2884. PubMed ID: 36636085
[TBL] [Abstract][Full Text] [Related]
16. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
17. Claudin18.2 expression in pulmonary mucinous adenocarcinoma.
Wang Y; Gao Y; Zhang Z; Zhang Z; Wang A; Zhao K; Zhang M; Zhang S; Li M; Sun J; Guo D; Liang Z
J Cancer Res Clin Oncol; 2023 Nov; 149(14):12923-12929. PubMed ID: 37466797
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience.
Kolarov Bjelobrk I; Radic J; Trifunovic J; Pesic J; Vidovic V; Vranjkovic B; Petrovic N; Andrejic Visnjic B
J Chemother; 2022 Jul; 34(4):264-271. PubMed ID: 34844517
[TBL] [Abstract][Full Text] [Related]
19. Expression and prognostic analysis of CLDN18 and Claudin18.2 in lung adenocarcinoma.
Liu J; Yang H; Yin D; Jia Y; Li S; Liu Y
Pathol Res Pract; 2022 Oct; 238():154068. PubMed ID: 36007395
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
